Therapeutic Assays of the Skin and Cancer Unit of the New York University Hospital1 Assay VII—Quinacrine Hydrochloride (Atabrine Hydrochloride) for Chronic Discoid Lupus Erythematosus by Sawicky, H.H. et al.
PRELIMINARY AND SHORT REPORTS
THERAPEUTIC ASSAYS OF THE SKIN AND CANCER UNIT OF THE
NEW YORK UNIVERSITY HOSPITAL*
ASSAY VII—QUINACRINE HYDROCHLORIDE (ATABRINE HYDROCHLORIDE) FOR
ChRONIC DISCOID Locus ERYTIIEMATO5U5
H. H. SAWICKY, M.D., NORMAN B. KANOF, M.D., MABEL C. SILVERBERG, M.D.,
MAX BRAITMAN, M.D. AND BEATRICE KALISH, M.D.
Just about a year has passed since the publication of the encouraging report by Page
(1) on the response of chronic discoid lupus erythematosus to Mepacrine® (Quinacrine
hydrochloride, U.S.P.) and the success of Dr. Jack Wolf (2) in the treatment of two cases
with this substance. During this interYal thirty patients haYe been under treatment with
Atabrine®1 at the New York Skin and Cancer Unit. Most of these patients had previously
received intensive therapy with other medicaments with varying results. The prompt and
generally favorable response to the drug seems to merit a preliminary report so that other
similar studies may he iDitiated. (See Table I.)
The basic dosage used in this series was 13 grains (0.1 Cm.) twice daily. In a few in-
stances, the dose was increased to 0.1 Cm. four times daily or reduced to 0.1 Cm. once
daily. Complete blood counts and urine examinations were made every two to three weeks.
Headache, nausea, vomiting and diarrhea were occasionally encountered. One pityriasis
rosea-like eruption was observed; but whether the eruption was an atabrine dermatitis or
a pityriasis rosea had not been determined at the time of this writing. No instances of men-
tal disturbance or blood dyscrasia have been observed. All patients noted yellowish pig-
mentation of the skin and/or the sclerae. They were told to expect this and did not find it
particularly disturbing.
The findings in this study support Page's observations. The great majority of cases
showed prompt and definite improvement (twenty-one cases). Some "cleared" completely
(six cases) and have not as yet relapsed. A few patients failed to respond satisfactorily
(three cases) or relapsed while on the therapy or soon after its cessation.
"New" and "superior" therapies for lupus erythematosus appear periodically in the
dermatologic literature. They are then evaluated with hopeful skepticism by the profession.
The prompt response of the majority of patients, and the relative safety of the drug (in
our study) warrant further use of Atabrine® in the therapy of chronic discoid lupus cry-
thematosus, so that its proper place in the treatment of this disease may be established.
If the chronic discoid form and the subacute and acute disseminated lupus erythematosus
are indeed etiologically the same disease, it may be hoped that Atabrine® will prove in-
valuable and perhaps life-saving in the more acute systelnic varieties. Careful studies with
Atabrine® combined with cortisone are now in progress in some of our patients with acute
disseminated lupus erythematosus.
[See Addeadurn on pope 404]
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404 THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
ADDENDUM
Since the preparation of the ahove article we have received a report of a death due to
aplastie anemia in a ease of lupus erythematosus which had been treated with Atahrine®.
Since the possibility exists that the anemia could have been due to the Atabrine, it will
he essential for all patients receiving the drug to have careful hematological examinations
before initiation of the treatment, and periodically and regularly during the course of
Atahrine administration. (Compare Rohinson, Zeligman, Shapiro, Cohen—Leukopeni a,
A Complication of Chloromyeetin Therapy of Chronic Discoid Lnpus Erythematosus.
J. Tnvest. Dermat. 19: 199, 1952.)
